JPWO2023288338A5 - - Google Patents
Info
- Publication number
- JPWO2023288338A5 JPWO2023288338A5 JP2024502009A JP2024502009A JPWO2023288338A5 JP WO2023288338 A5 JPWO2023288338 A5 JP WO2023288338A5 JP 2024502009 A JP2024502009 A JP 2024502009A JP 2024502009 A JP2024502009 A JP 2024502009A JP WO2023288338 A5 JPWO2023288338 A5 JP WO2023288338A5
- Authority
- JP
- Japan
- Prior art keywords
- expression cassette
- nucleotide sequence
- present
- sequence encoding
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222954P | 2021-07-16 | 2021-07-16 | |
| US63/222,954 | 2021-07-16 | ||
| US202163282961P | 2021-11-24 | 2021-11-24 | |
| US63/282,961 | 2021-11-24 | ||
| PCT/US2022/073862 WO2023288338A2 (en) | 2021-07-16 | 2022-07-18 | Polycistronic vectors for cell-based therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525789A JP2024525789A (ja) | 2024-07-12 |
| JP2024525789A5 JP2024525789A5 (https=) | 2025-07-17 |
| JPWO2023288338A5 true JPWO2023288338A5 (https=) | 2025-07-17 |
Family
ID=84919770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502009A Withdrawn JP2024525789A (ja) | 2021-07-16 | 2022-07-18 | 細胞ベースの療法のためのポリシストロニックベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250122529A1 (https=) |
| EP (1) | EP4370699A4 (https=) |
| JP (1) | JP2024525789A (https=) |
| KR (1) | KR20240046833A (https=) |
| AU (1) | AU2022312508A1 (https=) |
| CA (1) | CA3224974A1 (https=) |
| IL (1) | IL310099A (https=) |
| MX (1) | MX2024000713A (https=) |
| WO (1) | WO2023288338A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024216143A1 (en) * | 2023-04-14 | 2024-10-17 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function |
| WO2024233887A1 (en) * | 2023-05-10 | 2024-11-14 | Science Corporation | A hypoimmunogenic cell and methods of generation thereof |
| AU2024328949A1 (en) * | 2023-08-23 | 2026-03-12 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| CN116987699B (zh) * | 2023-09-05 | 2024-08-27 | 深圳市艾迪贝克生物医药有限公司 | 用于制备通用型car-t细胞的基因片段、其工具系统及应用 |
| WO2025151838A1 (en) * | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3498824A1 (en) * | 2013-04-26 | 2019-06-19 | Memorial Sloan-Kettering Cancer Center | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
| EP3418379B1 (en) * | 2013-09-18 | 2020-12-09 | Kymab Limited | Methods, cells & organisms |
| AU2017269364B2 (en) * | 2016-05-25 | 2023-08-31 | Salk Institute For Biological Studies | Compositions and methods for organoid generation and disease modeling |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| EP3346001A1 (en) * | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| US20210308183A1 (en) * | 2018-07-17 | 2021-10-07 | The Regents Of The University Of California | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
| SG11202104524YA (en) * | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| EP3883955A1 (en) * | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
| WO2020183131A1 (en) * | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CA3194577A1 (en) * | 2020-10-09 | 2022-04-14 | Sonja SCHREPFER | Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent |
-
2022
- 2022-07-18 MX MX2024000713A patent/MX2024000713A/es unknown
- 2022-07-18 KR KR1020247005288A patent/KR20240046833A/ko active Pending
- 2022-07-18 AU AU2022312508A patent/AU2022312508A1/en active Pending
- 2022-07-18 IL IL310099A patent/IL310099A/en unknown
- 2022-07-18 CA CA3224974A patent/CA3224974A1/en active Pending
- 2022-07-18 US US18/579,300 patent/US20250122529A1/en active Pending
- 2022-07-18 JP JP2024502009A patent/JP2024525789A/ja not_active Withdrawn
- 2022-07-18 WO PCT/US2022/073862 patent/WO2023288338A2/en not_active Ceased
- 2022-07-18 EP EP22843094.8A patent/EP4370699A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy | |
| Martin et al. | Engineering immune-evasive allogeneic cellular immunotherapies | |
| CN111479917A (zh) | 经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞 | |
| KR20230172630A (ko) | 종양 네오 항원성 펩타이드 | |
| JP2019533450A (ja) | 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体 | |
| US20250122529A1 (en) | Polycistronic vectors for cell-based therapies | |
| CN113227141A (zh) | 抗cd33免疫细胞癌症疗法 | |
| KR20230172047A (ko) | 종양 신생항원 펩타이드 및 이의 용도 | |
| US20250320290A1 (en) | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENT | |
| WO2019090202A1 (en) | Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy | |
| JPWO2023288338A5 (https=) | ||
| KR20250020432A (ko) | 조작 면역 세포를 이용한 자가면역 질환의 치료 | |
| Ueda et al. | Immunotherapy perspectives in the new era of B-cell editing | |
| EP3638783A1 (en) | Targeted disruption of t cell and/or hla receptors | |
| WO2021249384A1 (en) | Compositions and methods for enhancing immune response | |
| An et al. | “Off-the-shelf” allogeneic CAR cell therapy—neglected HvG effect | |
| Huang et al. | Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases | |
| JPWO2019210078A5 (https=) | ||
| JP2025532839A (ja) | 細胞に基づく治療を増強させるための抗体耐性改変受容体 | |
| Viret et al. | Functional and phenotypic evidence for presentation of Eα52–68 structurally related self-peptide (s) in I-Eα-deficient mice | |
| WO2021087305A1 (en) | Cd20 chimeric antigen receptors and methods of use for immunotherapy | |
| JPWO2019210042A5 (https=) | ||
| CN119156133A (zh) | 免疫缺陷fcgr1敲除小鼠模型 | |
| CN117957327A (zh) | 用于基于细胞的疗法的多顺反子载体 | |
| US20250222138A1 (en) | Site-specific in vivo t cell engineering, systems, compositions and methods thereof |